Skip to main content
Clinical Trials/NCT04956523
NCT04956523
Unknown
Not Applicable

Preliminary Tissue Monitoring During Endovascular Intervention Study

Pedra Technology, PTE LTD0 sites20 target enrollmentOctober 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peripheral Arterial Disease
Sponsor
Pedra Technology, PTE LTD
Enrollment
20
Primary Endpoint
Integration of Xauron System into clinical workflow - The Investigator will complete a questionnaire assessing that the Xauron system can be integrated within the angiography suite for all subjects observed.
Last Updated
4 years ago

Overview

Brief Summary

Tissue perfusion assessment is key to more accurate measurement of foot ischemia, which is in turn an important factor in appropriate treatment decisions. In practice though, tissue perfusion measurements are not routinely undertaken as few practical solutions exist that are easy to use and fit in everyday clinical practice. Pedra has developed a novel easy to use, non-invasive device that can be used in practice to better inform treatment decisions.

Detailed Description

Tissue perfusion assessment is key to more accurate measurement of foot ischemia, which is in turn an important factor in appropriate treatment decisions. In practice though, tissue perfusion measurements are not routinely undertaken as few practical solutions exist that are easy to use and fit in everyday clinical practice. Pedra has developed a novel, easy to use, non-invasive device that can be used in practice to better inform treatment decisions. This is a feasibility study to demonstrate the ability of the Xauron system to track tissue perfusion changes in patients undergoing endovascular intervention for the treatment of peripheral artery disease (PAD). The findings of this study are for research purposes and will also be used to help with the future education of physicians about the potential use of the Xauron system. In addition, this early pilot data will be used to help power larger, more definitive studies relating to the intra-procedural use of the Xauron system.

Registry
clinicaltrials.gov
Start Date
October 1, 2021
End Date
March 1, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The subject is undergoing endovascular intervention for the management of their PAD.
  • The subject is between 40 to 90 years of age.
  • Documented lower limb arterial occlusive or stenotic disease (using ankle-brachial index / pulse volume recording, duplex ultrasound or CT angiogram) within the last 8 weeks.
  • In the opinion of the Investigator, the subject is willing and able to comply with the protocol and complete all protocol assessments.
  • The subject has been informed of the nature of the study, agrees to its provisions and has willingly provided written informed consent, approved by the appropriate Institutional Review Board (IRB)

Exclusion Criteria

  • Subjects on an investigational drug or being treated with an investigational therapeutic device, within 30 days of the study visit, that in the view of the Investigator might interfere with the study outcomes.
  • Presence of a condition that the Investigator considers will compromise the subject's ability to participate in the study.
  • Subjects on renal replacement therapy
  • Signs of active infection causing localized inflammation on the plantar or dorsal surfaces of the foot.
  • Lack of intact skin, or pathological skin conditions, at the proposed sensor pad positions that may impair or prevent the adherence of medical adhesives in general.
  • Diabetic subjects with a Charcot neuropathic osteoarthropathy

Outcomes

Primary Outcomes

Integration of Xauron System into clinical workflow - The Investigator will complete a questionnaire assessing that the Xauron system can be integrated within the angiography suite for all subjects observed.

Time Frame: Measured at the SOC index procedure

To confirm that the Xauron system can be integrated into he angiography suite clinical workflow.

Secondary Outcomes

  • Relationship between interventional events of procedure and perfusion changed detected but the Xauron System(Measured at the standard of care (SOC) index procedure)
  • Relationship of perfusion data from different anatomical locations during procedure(Measured at the SOC index procedure)
  • User feedback from the team in the angiographic suite(Measured at the SOC index procedure)
  • Angiographic images to evaluate and understand perfusion monitoring(Measured at the SOC index procedure)

Similar Trials